AstraZeneca's COPD triple therapy slammed by CRL — falling further behind GSK
Days after touting key advances for its oncology strategy, AstraZeneca is being slapped by a regulator setback in the respiratory space.
The FDA has refused to approve PT010, a much-touted triple-drug combination for chronic obstructive pulmonary disease that it had hoped would challenge GlaxoSmithKline. The complete response letter followed an OK in Japan several months ago, pushing the drug onto the market as Breztri Aerosphere.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.